Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): May 19, 2015 (May 19, 2015)

 

 

Valeant Pharmaceuticals International, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia, Canada

(State or other jurisdiction of

incorporation or organization)

 

001-14956

(Commission

File Number)

 

98-0448205

(I.R.S Employer

Identification No.)

2150 St Elzear Blvd, West

Laval, Quebec H7L 4A8

Canada

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (514) 744-6792

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 19, 2015 the Company held its Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following three proposals, each of which is described in detail in the Management Proxy Circular and Proxy Statement. The results of each matter voted upon are as follows:

Proposal No. 1: Election of Directors. The following individuals were elected to the Company’s Board of Directors:

 

Name

   For      Withheld      Broker Non-
Votes
 

Ronald H. Farmer

     259,517,209         2,064,596         12,938,661   

Colleen A. Goggins

     260,564,263         1,017,542         12,938,661   

Robert A. Ingram

     258,725,145         2,856,660         12,938,661   

Anders Lönner

     259,632,031         1,949,774         12,938,661   

Theo Melas-Kyriazi

     260,811,015         770,790         12,938,661   

J. Michael Pearson

     255,809,687         5,772,118         12,938,661   

Robert N. Power

     258,849,981         2,731,824         12,938,661   

Norma A. Provencio

     260,777,276         804,529         12,938,661   

Howard B. Schiller

     250,437,448         11,144,357         12,938,661   

Katharine B. Stevenson

     260,656,695         925,110         12,938,661   

Jeffrey W. Ubben

     260,166,082         1,415,723         12,938,661   

Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.

 

                  For                   

                   Against                                     Abstain                           Broker Non-Votes      

235,933,677

   25,078,279    569,849    12,938,661

Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2016 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.

 

                  For                   

                   Withhold                           Broker Non-Votes      

273,095,124

   1,425,342    0


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

VALEANT PHARMACEUTICALS

INTERNATIONAL, INC.

Date: May 19, 2015 By:

 /s/ Robert R. Chai-Onn

Robert R. Chai-Onn

Executive Vice President, General Counsel

and Chief Legal Officer